AgroAmerica Supports Higher Education to Help Reduce Migration in Latin America
24.3.2021 14:00:00 EET | Business Wire | Press release
The Agribusiness food company, AgroAmerica, is sponsoring the 100K Innovation Fund grant competition for higher education projects aimed at universities in The United States, Central America and the Dominican Republic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005218/en/
The 100,000 Strong in the Americas Innovation Fund Grant Competition for higher education, promoted by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala, and the NGO Partners of the Americas, aims to impulse education initiatives through innovative models of academic training and student exchange programs between the United States and Central America & Dominican Republic, beginning in January 2022. Institutions of higher education in the United States and Guatemala, El Salvador, Honduras, Costa Rica, Panama, Belize, Nicaragua, and the Dominican Republic are invited to submit their 100K grant proposals to Partners of the Americas at 100kstrongamericas.org/grants before August 2, 2021. (Photo: Business Wire)
The 100K Innovation Fund New Grant Competition is sponsored by the Bureau of Western Hemisphere Affairs of the U.S. Department of State and supported by AgroAmerica, the U.S. Embassy in Guatemala and the NGO Partners of the Americas. The 100K Fund will be awarded in 12 grants of $25,000 this year to support new higher education projects.
AgroAmerica is the second multinational company in Guatemala to join this public-private initiative. The company's CEO, Fernando Bolaños Valle, said that "it is with great enthusiasm that AgroAmerica joins the State Department as a strategic partner in this regional initiative, in an organic way, because of our shared values; building, through educational programs, a more prosperous future full of hope for our countries… we are convinced that the future of our continent depends on strategic investments like these, which will multiply prosperity for the United States, Guatemala and the region."
Javier Aguirre, corporate director of AgroAmerica, explained that the company donated funds to strengthen local capacities in the areas of climate change, human rights, natural resource management, sustainable agriculture, conservation and reforestation, environmental protection and sustainable businesses.
"The new 100K Strong Americas Innovation Fund partnerships, supported by AgroAmerica and the Department of State, will grow the number of students in the United States, Central America and the Dominican Republic, so working together, they will acquire valuable new skills and knowledge and grow our economies," said Julie Chung, acting assistant secretary of the Bureau of Western Hemisphere Affairs at the U.S. Department of State.
About the 100K Innovation Fund
The 100,000 Strong in the Americas Innovation Fund is the public-private sector collaboration between the Department of State, U.S. embassies and Partners of the Americas to promote a positive agenda for the region by harnessing the power of education.
About AgroAmerica
AgroAmerica is an agribusiness company dedicated to the production and commercialization of food products, through the use of sustainable and responsible cultivation methods. It operates in Europe, the United States, Mexico, Guatemala, Ecuador, Peru, and Panama. The Company's Corporate Sustainability Strategy aims to generate value and balance between economic growth, natural resource conservation, and the wellbeing of customers, employees, and stakeholders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005218/en/
Contact information
Javier Aguirre
Corporate Director
comunicacion@agroamerica.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom